Benzinga | Nov 2, 2021 10:50AM EDT

Aclaris Therapeutics Q3 EPS $(0.35) Down From $(0.25) YoY, Sales $1.66M Up From $1.45M YoY

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.35) per share. This is a 40 percent decrease over losses of $(0.25) per share from the same period last year. The company reported $1.66 million in sales this quarter. This is a 14.49 percent increase over sales of $1.45 million the same period last year.